Please login to the form below

Not currently logged in
Email:
Password:

LigoCyte

This page shows the latest LigoCyte news and features for those working in and with pharma, biotech and healthcare.

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine

Takeda acquired rights to TAK-214 when it bought US biopharma company LigoCyte in 2012 in a $60m deal and says it remains the only norovirus vaccine candidate in clinical development.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... 64. LigoCyte /Takeda. Acquisition. VLP-based vaccines for GI &respiratory infections (lead product phase I/II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...